Ideaya Biosciences, announced that the FDA has completed its safety review of the investigational new drug, or IND, application and concluded that Ideaya s proposed clinical study may proceed to evaluate IDE161 in solid tumors.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IDYA:
- Buy/Sell: Wall Street’s top 5 stock calls this week
- Capital One starts Ideaya Biosciences at Overweight with $29 price target
- Ideaya Biosciences initiated with an Overweight at Capital One
- Ideaya Biosciences to host virtual investor research and development day
- Ideaya Biosciences granted fast track designation for darovasertib
